FDA Launches Emergency Program to Expedite the Development of COVID-19 Treatments

FDA Launches Emergency Program to Expedite the Development of COVID-19 Treatments

Shots:

  • The US FDA has launched Coronavirus Treatment Acceleration Program (CTAP) to expedite the development of safe and effective drugs targeting COVID-19. FDA’s CTAP is a tool to bring new therapies to the patients as soon as possible
  • Under CTAP, FDA is redeploying staff and streamlining processes to hasten the reviews of clinical trial protocols and single-patient expanded-access requests
  • FDA unveiled that 10 therapeutic agents are in active trials and 15 agents in the planning stages. The FDA highlights some treatments that are currently being investigated for COVID-19 including Gilead’s remdesivir, Roche’s Actemra (tocilizumab) and Sanofi & Regeneron’s Kevzara (sarilumab)

Source 1, Source 2 ­to­ read full press release/ article | Ref: Eyewire, FDA | Image: FDA